Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
Atossa (NASDAQ: ATOS) appointed Mark Daniel, CPA, as Chief Financial Officer effective Oct 14, 2025 to lead finance, systems, and capital strategy as the company prepares for commercial launch of (Z)-endoxifen.
Mr. Daniel brings >25 years of life‑sciences finance experience, including weekly revenue forecasting with commercial teams, management of operating budgets >$200M, implementation and certification of SOX controls, programs delivering >$50M in cost savings, stewardship of a $400M cash and investments portfolio, and participation in nearly $1B of equity, convertible debt, and credit transactions.
Atossa (NASDAQ: ATOS) ha nominato Mark Daniel, CPA, come Chief Financial Officer con effetto dal 14 ottobre 2025, per guidare finanza, sistemi e strategia di capitale mentre l'azienda si prepara al lancio commerciale di (Z)-endoxifen.
Il signor Daniel porta oltre 25 anni di esperienza finanziaria nel settore delle scienze della vita, tra cui previsioni di fatturato settimanali con i team commerciali, gestione di budget operativi superiori a 200 milioni di dollari, implementazione e certificazione dei controlli SOX, programmi che hanno generato oltre 50 milioni di dollari in risparmi sui costi, la gestione di un portafoglio di liquidità e investimenti di 400 milioni di dollari e la partecipazione a quasi 1 miliardo di dollari di operazioni azionarie, debito convertibile e credito.
Atossa (NASDAQ: ATOS) nombró a Mark Daniel, CPA, como Director Financiero (CFO) con efecto a partir del 14 de oct de 2025 para liderar finanzas, sistemas y estrategia de capital mientras la empresa se prepara para el lanzamiento comercial de (Z)-endoxifen.
El señor Daniel aporta más de 25 años de experiencia en finanzas de ciencias de la vida, incluida la previsión de ingresos semanal con equipos comerciales, la gestión de presupuestos operativos superiores a 200 millones de dólares, la implementación y certificación de controles SOX, programas que generan más de 50 millones de dólares en ahorros de costos, la gestión de una cartera de efectivo e inversiones de 400 millones de dólares y la participación en casi 1.000 millones de dólares en transacciones de acciones, deuda convertible y crédito.
Atossa (NASDAQ: ATOS)는 2025년 10월 14일부로 Mark Daniel, CPA를 최고재무책임자(CFO)로 임명하여, 상업 출시를 준비 중인 (Z)-endoxifen의 재무, 시스템 및 자본 전략을 주도하게 합니다.
다니엘 씨는 생명과학 분야의 재무 경력이 25년 이상으로, 상업팀과의 주간 매출 예측, 2억 달러를 상회하는 운영 예산 관리, SOX 통제의 구현 및 인증, 비용 절감 5천만 달러를 창출하는 프로그램, 4억 달러 규모의 현금 및 투자 포트폴리오 관리, 그리고 거의 10억 달러 규모의 주식, 전환사채, 신용 거래에 참여한 경험을 보유하고 있습니다.
Atossa (NASDAQ: ATOS) a nommé Mark Daniel, CPA, comme Directeur Financier (CFO) à compter du 14 octobre 2025 pour piloter les finances, les systèmes et la stratégie de capital alors que l'entreprise se prépare au lancement commercial de (Z)-endoxifen.
M. Daniel apporte plus de 25 ans d'expérience en finance des sciences de la vie, notamment des prévisions de revenus hebdomadaires avec les équipes commerciales, la gestion de budgets opérationnels supérieurs à 200 millions de dollars, la mise en œuvre et la certification des contrôles SOX, des programmes générant plus de 50 millions de dollars d'économies, la gestion d'un portefeuille de trésorerie et d'investissements de 400 millions de dollars et la participation à près d'un milliard de dollars d'opérations sur actions, dette convertible et crédit.
Atossa (NASDAQ: ATOS) hat Mark Daniel, CPA, zum Chief Financial Officer ab dem 14. Oktober 2025 ernannt, um die Finanzen, Systeme und Kapitalstrategie zu leiten, während das Unternehmen sich auf den kommerziellen Start von (Z)-Endoxifen vorbereitet.
Herr Daniel verfügt über mehr als 25 Jahre Erfahrung im Finanzbereich der Lebenswissenschaften, einschließlich wöchentlicher Umsatzprognosen mit Vertriebsteams, Verwaltung von operativen Budgets von über 200 Mio. USD, Implementierung und Zertifizierung von SOX-Kontrollen, Programmen, die mehr als 50 Mio. USD an Kosteneinsparungen liefern, Verwaltung eines Bar- und Investmentportfolios von 400 Mio. USD und Teilnahme an nahezu 1 Mrd. USD an Eigenkapital-, Wandel- und Kredittransaktionen.
Atossa (NASDAQ: ATOS) عيّنت Mark Daniel، CPA، كـ المدير المالي التنفيذي اعتباراً من 14 أكتوبر 2025 لقيادة المالية والأنظمة واستراتيجية رأس المال بينما تستعد الشركة لإطلاق تجاري لـ (Z)-endoxifen.
يملك السيد دانيال أكثر من 25 عاماً من الخبرة المالية في علوم الحياة، بما في ذلك التنبؤ بالإيرادات الأسبوعي مع فرق التسويق، إدارة ميزانيات تشغيلية تتجاوز 200 مليون دولار، تنفيذ واعتماد ضوابط SOX، وبرامج توفر أكثر من 50 مليون دولار من وفورات التكاليف، والإشراف على محفظة نقدية واستثمارية بقيمة 400 مليون دولار، والمشاركة في ما يقرب من مليار دولار من صفقات الأسهم والديون القابلة للتحويل والائتمان.
Atossa (NASDAQ: ATOS) 任命 Mark Daniel, CPA, 为首席财务官，自 2025 年 10 月 14 日起生效，领导财务、系统与资本策略，正为公司即将商业化推出 (Z)-endoxifen 做准备。
Daniel 先生拥有生物医药领域超过 25 年的财务经验，包括与商业团队共同进行周度收入预测、管理超过 2亿美元的运营预算、实施并认证 SOX 控制、推进实现超过 5000 万美元的成本节省的项目、管理 4 亿美元的现金及投资组合以及参与近 10 亿美元的股票、可转债与信贷交易。
- Established weekly revenue-forecasting partnership with commercial teams
- Managed operating expense budgets exceeding $200M
- Implemented SOX controls and reduced SOX spend by >$2M/year
- Led programs delivering >$50M in cost savings
- Managed $400M cash and investments portfolio
- Supported execution of nearly $1B in financing transactions
- None.
25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen
Mr. Daniel also brings deep treasury and capital-markets expertise relevant to Atossa's transition from clinical development to commercialization. He has managed a
"As we prepare to evolve into a commercial company, we're focused on three things: revenue-ready systems, disciplined spend, and milestone-aligned financing," said Steven Quay, M.D., Ph.D., Atossa Chairman and Chief Executive Officer. "Mark has built and run that playbook in public life-science companies, standing up weekly revenue forecasts with sales, installing ERP/BI visibility from bookings to cash, tightening controls, and ensuring liquidity through volatile markets. His skill set is exactly what we need to support the planned launch path for (Z)-endoxifen."
"I'm excited to help Atossa operationalize commercial readiness—from FP&A cadence and revenue forecasting to capital planning and investor engagement," said Mr. Daniel. "Our aim is to align spending with value-creating milestones, strengthen the systems that support scale, and pursue a balanced financing strategy to enable a high-quality, efficient market entry."
Why This Hire Matters Now for Atossa's Commercial Transition
- Revenue Engine & Visibility: Weekly revenue-forecasting partnership with global sales; ERP/CRM/BI stewardship to unify bookings-to-cash and improve plan-to-actual accuracy.
-
Financial Discipline at Scale: Public-company reporting and compliance, SOX remediation to clean audits, in-house compliance that reduced SOX spend by >
$2M $50M - Capital Strategy: Managed significant cash and investment portfolios; Partnered on various forms of equity, convertible debt, and credit facilities; experience in structuring financing around operational milestones to help minimize dilution while funding growth.
- Global Operations Support: Leadership of international subsidiaries and supply agreements that enable scale and margin discipline.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative therapies for significant unmet needs in breast cancer. Atossa's strategy emphasizes disciplined capital allocation, focusing resources on programs and data packages that can enable future regulatory submissions and potential commercialization. For more information, visit www.atossatherapeutics.com and refer to Atossa's filings with the
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding Atossa's commercial readiness, financing strategy, operational plans, and the development and potential commercialization of (Z)-endoxifen. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including market conditions, regulatory outcomes, clinical results, manufacturing and supply, intellectual-property challenges, and the Company's ability to secure sufficient funding on acceptable terms. For a discussion of risks and uncertainties, please refer to Atossa's filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-appoints-mark-daniel-cpa-as-chief-financial-officer-to-lead-finance-systems-and-capital-strategy-for-commercial-readiness-302581513.html
SOURCE Atossa Therapeutics Inc
FAQ
Who is the new CFO of Atossa and when was the appointment announced?
What experience does Atossa CFO Mark Daniel bring that matters for ATOS commercialization?
How will Mark Daniel affect Atossa's capital strategy for (Z)-endoxifen commercialization?
What cost and control improvements does the new CFO have a record of delivering?
Will Mark Daniel oversee revenue forecasting for ATOS and how often?
